Tamarin study update and a new study now recruiting

[Mazcd]

Tamarin Study

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms – ET/PV and MF

The TAMARIN study has been running in 13 hospitals across the UK since 2018 and to date the preliminary results are very exciting. The study is a multicentre phase II clinical trial which will assess the safety and activity of Tamoxifen in MPNs. There are still 5 places left on this study, if you would like to take part in this study you will need to discuss it with your haematologist, or you can contact MPN Voice for further information - email [e-mail].

Full details of the study can be found here mpnvoice.org.uk/documents/T...

KRT-232-101 Phase 2 Clinical Study

KRT-232-101 is a Phase 2a-2b, global, open-label study of KRT-232 in patients with Primary Myelofibrosis, post-Polycythaemia Vera Myelofibrosis, or post-Essential Thrombocythaemia Myelofibrosis who have failed previous treatment with a JAK inhibitor; and in patients with phlebotomy-dependent Polycythaemia Vera.

In PART A, patients must be resistant or intolerant to Hydroxyurea (Hydroxycarbamide) or have undergone treatment with interferon. In PART B, patients must be resistant or intolerant to Hydroxyurea (Hydroxycarbamide).

Locations running this study are in the UK and the USA, details are available on the link below.

Full details for the study can be found on the ClinicalTrials.gov website

clinicaltrials.gov/ct2/show...

If you would like to take part in this trial you will need to discuss it with your haematologist.

Interested in taking part in a study or research? Read more on our website about trials and research which are currently recruiting mpnvoice.org.uk/about-mpns/...

or speak to your haematologist, or search on the ClinicalTrials.gov website, which lists all trials and studies across the world. clinicaltrials.gov/